• Validation of validity, superiority, and safety of data analysis results using AT-Patch compared to 48-hour Holter test results
• Number of subjects: 100 (including 10% dropout rate)
• Performance and safety were verified by simultaneously attaching a 48-hour Holter and a wearable Holter device (ATP-C75 or ATP-C135).

Prospective, sequential, superiority test Patients diagnosed with hypertrophic cardiomyopathy who require 48-hour Holter monitoring.

• 48-hour Holter vs ATP-C75 (48-hour comparison/total time comparison)
• 48-hour Holter vs ATP-C135 (48-hour comparison/total time comparison)
• Comparison between IDs

Inclusion Criteria:

1. Male and female subjects aged 19 years or older
2. Subjects diagnosed with hypertrophic cardiomyopathy who require 48-hour Holter examination

Exclusion Criteria:

1. Those judged by the investigator to be unsuitable for this clinical trial or those who may increase the risk due to participation in the clinical trial
2. Those with sensitive or allergic skin, skin diseases such as skin cancer or rashes
3. Those with pacemakers, implantable cardioverter-defibrillators, or other implantable electrical devices
4. Pregnant women

The individual data of the subjects will be pseudonymized/anonymized in accordance with ICH GCP and recorded in the case record sheet, and only the participating researchers will be able to access the data. Monitoring will be conducted by a monitor designated by the client to conduct SDV, and the CRF for which SDV has been completed will be collected at the end of the study with the signature of the PI.